CommercialPrior AuthMedium impact
Idecabtagene Vicleucel (Abecma) (CPB 0992, reviewed 2025-12-19)
Aetna·Oncology, Hematology·Medical Policy
Effective date
Dec 19, 2025
We identified it
Aug 15, 2026
Summary
Aetna has issued a fresh clinical policy bulletin (CPB 0992) establishing coverage criteria for Idecabtagene Vicleucel (Abecma), a CAR-T cell immunotherapy for relapsed or refractory multiple myeloma. The policy requires precertification for all claims, restricts coverage to patients meeting strict eligibility criteria (including prior treatment with at least 2 lines of therapy from specific drug classes and exclusions for CNS pathology), and covers only HCPCS code Q2055 with associated CAR-T harvesting and preparation codes when criteria are met.
Action Required
IMMEDIATELY: (1) Billing team must implement precertification requirement for all Abecma claims by contacting Aetna's National Medical Excellence (NME) at 877-212-8811 before any treatment. Update billing software to flag HCPCS Q2055 and CPT 38225-38228 with mandatory prior auth requirement. (2) Add eligibility verification checklist to ensure patients meet ALL criteria before billing: minimum 2 prior therapy lines (including immunomodulatory agent, proteasome inhibitor, and anti-CD38 monoclonal antibody), ECOG 0-2, adequate organ function, NO CNS involvement or pathology, NO active infection/GVHD/inflammatory disorders, and NO prior CAR-T therapy. (3) Providers must document all exclusion criteria verification in medical record. (4) Claims submitted without precertification approval or incomplete eligibility documentation will be denied. (5) Ensure billing team understands Q2055 is the only covered HCPCS code; all other indications (solid tumors, etc.) are experimental and not covered. Do not submit claims for non-approved indications.